Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7515629
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RO7515629 is a bispecific T-cell engager (BiTE) antibody developed by Roche. It targets both CD3 on cytotoxic T lymphocytes and HLA-G, an immune checkpoint molecule expressed on certain tumor cells. By binding to CD3, it stimulates T-cell activation, while inhibition of HLA-G aims to overcome tumor-induced immune suppression. The drug was investigated for its potential in treating advanced or metastatic solid tumors expressing HLA-G, including colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma, renal cell carcinoma (RCC), ovarian neoplasms, and other solid tumors. Clinical development reached Phase 1 but was discontinued due to sponsor decision unrelated to safety or efficacy[1][4][7].
- Other names
- anti-HLA-G/CD3 bispecific antibody RO7515629
02
Targets
HLA-G (Human leukocyte antigen G)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on RO7515629.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7515629.